Abstract

Positive allosteric modulators (PAMs) of α4β2 nicotinic acetylcholine receptors have the potential to improve cognitive function and alleviate pain. However, only a few selective PAMs of α4β2 receptors have been described limiting both pharmacological understanding and drug-discovery efforts. Here, we describe a novel selective PAM of α4β2 receptors, NS206, and compare with a previously reported PAM, NS9283. Using two-electrode voltage-clamp electrophysiology in Xenopus laevis oocytes, NS206 was observed to positively modulate acetylcholine (ACh)-evoked currents at both known α4β2 stoichiometries (2α:3β and 3α:2β). In the presence of NS206, peak current amplitudes surpassed those of maximal efficacious ACh stimulations (Emax(ACh)) with no or limited effects at potencies and current waveforms (as inspected visually). This pharmacological action contrasted with that of NS9283, which only modulated the 3α:2β receptor and acted by left shifting the ACh concentration-response relationship. Interestingly, the two modulators can act simultaneously in an additive manner at 3α:2β receptors, which results in current levels exceeding Emax(ACh) and a left-shifted ACh concentration-response relationship. Through use of chimeric and point-mutated receptors, the binding site of NS206 was linked to the α4-subunit transmembrane domain, whereas binding of NS9283 was shown to be associated with the αα-interface in 3α:2β receptors. Collectively, these data demonstrate the existence of two distinct modulatory sites in α4β2 receptors with unique pharmacological attributes that can act additively. Several allosteric sites have been identified within the family of Cys-loop receptors and with the present data, a detailed picture of allosteric modulatory mechanisms of these important receptors is emerging.

Highlights

  • Positive allosteric modulators (PAMs) of ␣4␤2 nicotinic acetylcholine receptors have significant therapeutic potential

  • Aligning pharmacological actions for a range of PAMs with their proposed binding sites, it appears that binding in extracellular domain (ECD) interfaces mostly result in agonist CRR left shifts, whereas transmembrane domain (TMD) binding can further result in increased agonist-evoked peak currents, delayed desensitization characteristics, and direct agonist independent receptor activation

  • NS206 (Fig. 1A) was initially identified as a PAM of ␣4␤2 nicotinic acetylcholine receptors (nAChRs) in a screening campaign aimed at identifying allosteric modulators from compound libraries

Read more

Summary

Background

Positive allosteric modulators (PAMs) of ␣4␤2 nicotinic acetylcholine receptors have significant therapeutic potential. Additive Allosteric Modulation of ␣4␤2 nAChRs waveforms, whereas PNU-120596 delay desensitization resulting in large current waveform changes It appears that at least three different modulatory phenotypes can be observed in the Cys-loop receptor family: (i) left-shift of the agonist CRR, (ii) increased peak current levels above Emax of the endogenous agonist, and (iii) delay of desensitization. Aligning pharmacological actions for a range of PAMs (literature and current study) with their proposed binding sites, it appears that binding in ECD interfaces mostly result in agonist CRR left shifts, whereas TMD binding can further result in increased agonist-evoked peak currents, delayed desensitization characteristics, and direct agonist independent receptor activation

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call